Deutetrabenazine?

Deutetrabenazine is a medication used to treat chorea associated with Huntington's disease and tardive dyskinesia [1]. It works by reducing the amount of dopamine in the brain [2].

How is Deutetrabenazine Different from Tetrabenazine?

Deutetrabenazine is a deuterium-modified version of tetrabenazine. The modification involves replacing certain hydrogen atoms with deuterium. This change in molecular structure alters how the drug is metabolized in the body, leading to a longer half-life and potentially reduced peak plasma concentrations compared to tetrabenazine [1][3]. This difference in metabolism may allow for a less frequent dosing schedule and a different side effect profile for deutetrabenazine [3].

When Does Deutetrabenazine's Patent Protection End?

The patent protection for deutetrabenazine varies by patent and region. Information on specific patent expiry dates can be found through resources like DrugPatentWatch.com [4]. The duration of patent exclusivity is crucial for understanding when generic versions of the drug might become available.

What are the Potential Side Effects of Deutetrabenazine?

Common side effects of deutetrabenazine include drowsiness, fatigue, insomnia, nausea, and dizziness [1]. It is important to note that deutetrabenazine can also cause or worsen depression and suicidal thoughts. Patients taking this medication should be closely monitored for any changes in mood or behavior [1][5].

Who Manufactures Deutetrabenazine?

Deutetrabenazine is manufactured by Sun Pharmaceutical Industries Ltd. [1].

How is Deutetrabenazine Administered?

Deutetrabenazine is typically taken orally, either as tablets or capsules [1]. Dosing is usually adjusted based on the patient's response and tolerance [1].